GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » Cash Conversion Cycle

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Quoin Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was .
Quoin Pharmaceuticals's Days Inventory for the three months ended in Mar. 2024 was .
Quoin Pharmaceuticals's Days Payable for the three months ended in Mar. 2024 was .
Therefore, Quoin Pharmaceuticals's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 0.00.


Quoin Pharmaceuticals Cash Conversion Cycle Historical Data

The historical data trend for Quoin Pharmaceuticals's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals Cash Conversion Cycle Chart

Quoin Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
- - - - -

Quoin Pharmaceuticals Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Quoin Pharmaceuticals's Cash Conversion Cycle

For the Biotechnology subindustry, Quoin Pharmaceuticals's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Quoin Pharmaceuticals's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's Cash Conversion Cycle falls into.



Quoin Pharmaceuticals Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Quoin Pharmaceuticals's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Quoin Pharmaceuticals's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Quoin Pharmaceuticals  (NAS:QNRX) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Quoin Pharmaceuticals Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Executives
Dennis Langer director C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper director PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell director C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn officer: Chief Financial Officer AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter director, officer: Chief Operating Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun director AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers director, officer: Chief Executive Officer AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Headlines

From GuruFocus